Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
The DJS Law Group issued a shareholder-solicitation notice announcing a securities class action against Capricor Therapeutics, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The complaint alleges Capricor modified the statistical analysis plan for clinical data on its drug Deramiocel without first securing the FDA's agreement, before resubmitting a Biologics License Application for the drug. The proposed class period runs December 17, 2025 through July 26, 2026, with a lead plaintiff deadline of September 28, 2026.
Key figures
- Class period end
- July 26, 2026
- Class period start
- December 17, 2025
- Lead plaintiff deadline
- September 28, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.